A Phase 2 Study to Evaluate the Efficacy and Safety of TNX-102 SL in Patients With Multi-Site Pain Associated With Post-Acute Sequelae of SARS-CoV-2 Infection
Study sponsor: Tonix Pharmaceuticals, Inc.
Primary completion is the date data collection ends for the main study measures, not when results are published.
Primary completion2023-07-12Actual
Enrollment · participants63Actual
Source updated2024-11-26Last update listed in the registry record
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.